Figure 1 | British Journal of Cancer

Figure 1

From: Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

Figure 1

Mean (s.d.) plasma concentration–time curves of pazopanib (A) and total topotecan (B) during part 1 (P1) following single administration of pazopanib (day 14, n =7), single administration of topotecan (day 1, n =6) and concomitant administration of pazopanib and topotecan (day 15); (C) Plasma concentration–time curves per patient treated with 8 mg topotecan weekly and 800 mg pazopanib daily in P2A and (D) treated with 2.5 mg topotecan daily-times-five and 800 mg pazopanib daily in P2B.

Back to article page